Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Cancers

Sushma Jonna¹  Karam Khaddour¹  Hossein Borghaei²  Alexander Deneka³  Erica Golemis³  Mohamed E. Abazeed⁴  Jyoti D. Patel⁵  Yanis Boumber⁵ 

[1]Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA

[2]Fox Chase Cancer Center, Department of Hematology and Oncology, Philadelphia, PA 19111, USA

[3]Fox Chase Cancer Center, Program in Molecular Therapeutics, Philadelphia, PA 19111, USA

[4]Robert H. Lurie Comprehensive Cancer Center, Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

[5]Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

关键词: lung cancer;    adenocarcinoma;    overall survival;    EGFR;    tyrosine kinase inhibitors;    progression-free survival;   

DOI  :  10.3390/cancers13133164

来源: DOAJ

【 摘 要 】

Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent and acquired resistance constitute a major challenge to the longitudinal treatment. Ongoing work is aimed at understanding the molecular basis of these resistance mechanisms, with exciting new studies evaluating novel agents and combination therapies to improve control of tumors with all forms of EGFR mutation. In this review, we first provide a discussion of EGFR-mutated lung cancer and the efficacy of available EGFR TKIs in the clinical setting against both common and rare EGFR mutations. Second, we discuss common resistance mechanisms that lead to therapy failure during treatment with EGFR TKIs. Third, we review novel approaches aimed at improving outcomes and overcoming resistance to EGFR TKIs. Finally, we highlight recent breakthroughs in the use of EGFR TKIs in non-metastatic EGFR-mutated lung cancer.

【 授权许可】

Unknown